Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

Original reporting
Published Oct 29, 2026, 9:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$PHATBullishMed
01

Why it matters

Near-term trading focus is likely on (1) durability of cash-flow positivity and operating profitability, (2) whether the Access First initiatives translate into sustained prescription growth, and (3) the credibility of the Q4 2026 Phase II EoE data timeline that could support pediatric exclusivity discussions. The VOQUEZNA exclusivity litigation is a key overhang for valuation and competitive dynamics.

02

Market read

Company-specific earnings and guidance details plus a defined clinical catalyst window can drive biotech positioning, while exclusivity litigation adds headline risk.

03

What to watch

The VOQUEZNA exclusivity litigation and the IQVIA methodology adjustment could complicate interpretation of prescription trends and future category share assumptions.

Relevance 7/10Novelty 6/10Timing: after-hours earnings call summary, positioning ahead of Q4 2026 EoE Phase II data

Background

Phathom’s call centers on a commercial pivot labeled “Access First,” aiming to improve adoption through prior authorization education and a $0 copay program via BlinkRx, alongside continued investment in late-stage trials and GI portfolio expansion.

Company-level read

Ticker impact

$PHATBullishMedium confidence
Context

Phathom reported Q3 revenue growth to $84.7M, reiterated 2026 guidance of $310M-$325M, and discussed Q4 2026 Phase II EoE data timing.

Expected impact

Likely upward bias as investors price in improving cash generation and near-term clinical catalysts, with volatility around the exclusivity litigation.

Evidence & confidence

The article contains multiple company-specific operating datapoints (revenue, cash flow, prescriptions) plus a concrete upcoming clinical milestone (Phase II EoE data in Q4 2026) and an ongoing legal overhang tied to VOQUEZNA exclusivity.

Market effects

Highlights continued commercialization focus in GI specialty pharma, including prior authorization workflow optimization and channel partnerships.

No clear regional market mechanism beyond US biotech sentiment.

Limited, as the catalysts described are company-specific and US regulatory/clinical-path related.

Counterpoint

The cash-flow and revenue momentum may still be fragile if gross-to-net discounts remain elevated and prior authorization success depends on execution that could vary by office and payer.

Key entities

  • Phathom Pharmaceuticals, Inc.

    Subject of the earnings call summary, providing Q3 operating metrics, 2026 revenue guidance, and upcoming Phase II EoE timing.

  • VOQUEZNA

    Phathom’s GI therapy discussed in the context of exclusivity litigation and commercial adoption initiatives.

  • BDR Pharmaceuticals

    Litigant challenging the FDA’s 10-year NCE exclusivity grant for VOQUEZNA under the GAIN Act.

  • BlinkRx

    Pharmacy partnership used to deliver a $0 copay offering and influence prior authorization and refill dynamics.

  • FDA

    Regulatory authority referenced for NCE exclusivity and for future Phase III design and pediatric exclusivity discussions.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.

$PHATMedAI 8/10

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals, Inc. (PHAT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update • Over 2 million total VOQUEZNA ® prescriptions filled through October 16, 2026 • Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 • G